| P2093 | author name string | U. Müller-Ladner | |
| | C. Hamm | |
| | I. H. Tarner | |
| P2860 | cites work | The Journal of Rheumatology | Q7743623 |
| | Effect of anti–tumor necrosis factor α therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis | Q57307126 |
| | Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy | Q57819586 |
| | Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart | Q71102878 |
| | Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure | Q73549952 |
| | How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH | Q78482942 |
| | Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients | Q79808209 |
| | Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab | Q79996729 |
| | Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis | Q80194544 |
| | Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate | Q80201780 |
| | Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? | Q80800883 |
| | ??? | Q28295371 |
| | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study | Q24630541 |
| | Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. | Q33436848 |
| | IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial | Q34795777 |
| | Case reports of heart failure after therapy with a tumor necrosis factor antagonist | Q35130706 |
| | Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register | Q35637343 |
| | Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy | Q35676074 |
| | Considerations with the use of biological therapy in the treatment of rheumatoid arthritis | Q35873708 |
| | All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists | Q35954490 |
| | Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis | Q36204149 |
| | TNFalpha blockade in human diseases: an overview of efficacy and safety | Q36536861 |
| | Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register | Q36732112 |
| | Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists | Q36742762 |
| | Infliximab improves vascular stiffness in patients with rheumatoid arthritis | Q37245192 |
| | Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. | Q37321296 |
| | Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis | Q38465160 |
| | Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis. | Q39672399 |
| | Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. | Q40312662 |
| | Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis | Q43049221 |
| | Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure | Q43826696 |
| | Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis | Q44187483 |
| | Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis | Q45129989 |
| | Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis | Q46075758 |
| | Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. | Q46632190 |
| | How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? | Q46732422 |
| | Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody | Q47368581 |
| | Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu | Q47849023 |
| | Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). | Q47945239 |
| | Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. | Q51464070 |
| | Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. | Q53547618 |
| | Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. | Q55049410 |
| P433 | issue | 8 | |
| P407 | language of work or name | German | Q188 |
| P304 | page(s) | 702-6, 708-11 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Zeitschrift fuer Rheumatologie | Q15763293 |
| P478 | volume | 69 | |